GlassScriptPhysician profile
Afshan Khan
NPI 1942682471
$952.98
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $226 · 2021: $149 · 2024: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $122.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $330.88 | 2019-2020 | |
| Glaxosmithkline, LLC. | $146.95 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $122.46 | 2024 | Lifevest |
| Novo Nordisk INC | $58.26 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $37.40 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.12 | 2019-2020 | |
| Amgen INC. | $30.35 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $26.82 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.56 | 2021 | |
| Allergan, INC. | $23.76 | 2020 | |
| Merck Sharp & Dohme LLC | $23.62 | 2019 | |
| Abbvie INC. | $16.06 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.12 | 2019 | |
| Amarin Pharma, INC. | $14.44 | 2020 | |
| Genentech USA, INC. | $13.38 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $12.58 | 2019 | |
| Shire North American Group INC | $11.98 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afshan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.